- Home
- BBAR vs NAMS Comparison
BBAR vs NAMS Comparison
Compare BBAR & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBAR | NAMS |
|---|---|---|
| Founded | 1886 | 2019 |
| Country | Argentina | Netherlands |
| Employees | N/A | 100 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | BBAR | NAMS |
|---|---|---|
| Price | $19.79 | $28.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $17.00 | ★ $46.75 |
| AVG Volume (30 Days) | 480.5K | ★ 904.9K |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.32 | $17.96 |
| Revenue Next Year | $11.04 | $540.65 |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.76 | $21.14 |
| 52 Week High | $22.47 | $42.21 |
Technical Indicators
Market Signals| Indicator | BBAR | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 35.54 |
| Support Level | $18.59 | N/A |
| Resistance Level | $19.21 | $37.29 |
| Average True Range (ATR) | 1.07 | 1.84 |
| MACD | -0.22 | -0.56 |
| Stochastic Oscillator | 19.07 | 5.38 |
Price Performance
Historical ComparisonAbout BBAR Banco BBVA Argentina S.A. ADS
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.